For Media Inquiries, Please Contact:
Global Corporate Affairs
150 Signet Drive
ON, M9L 1T9
April 21, 2020Canada’s Apotex Donates Two Million Dosages of Hydroxychloroquine to the Public Health Agency of Canada
April 17, 2020
April 13, 2020Canada's Largest Pharmaceutical Company Produces Hand Sanitizer to Support the Fight Against COVID-19
March 20, 2020Apotex Donates Hydroxychloroquine for a Clinical Study to Prevent Infection From Covid-19 With Front Line Health Care Workers
February 4, 2020Voluntary Recall of APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) 500mg Tablets.
December 5, 2019Canada’s leading generic drug manufacturer, Apotex, announced today that its first shipment of the drug tamoxifen has been released to the Canadian market. Additional releases are scheduled for December 2019 and January 2020.
June 1, 2018Health Canada Leads the Way by Approving the First-Ever Pegfilgrastim Biosimilar in any Highly Regulated World Market
September 1, 2017VOLUNTARY NATIONWIDE RECALL: One lot of APO-NITROGLYCERIN (Nitroglycerin Sublingual Spray) Apotex standard, 0.4MG/Metered dose due to possibility of non-spraying pump
February 9, 2017VOLUNTARY NATIONWIDE RECALL: One lot of ALYSENA™ 28 (Levonorgestrel and Ethinyl Estradiol tablets, USP 100 mcg/20 mcg) Due to Possibility of Broken/Chipped Tablets
March 31, 2016Apobiologix®, a Division of Apotex Inc., today launched Grastofil®, its first subsequent entry biologic (SEB) approved in Canada.
March 24, 2016Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex® nasal spray (mometasone furoate monohydrate) in the United States.